P0903: Structured yoga practices significantly improve quality of life in patients with Ulcerative Colitis in clinical remission: a randomized controlled trialECCO'25Year: 2025
Authors: Kalum , J.D.B.S.(1)*;Narang, H.(1);Virmani, S.(1);Shukla, A.(2);Verma, M.(1);Madan, D.(1);Kumar, P.(1);Mathew, D.(1);Prasad, S.(1);Mubunnu, M.(1);Kedia, S.(1);Makharia, G.(1);Sharma, G.(2);Ahuja, V.(1);
(1)All India Institute of Medical Sciences, Department of Gastroenterology and Human Nutrition, New Delhi, India;(2)All India Institute of Medical Sciences, Centre for Integrative Medicine and Research CIMR, New Delhi, India;
1. Sharma P, Poojary G, Dwivedi SN, Deepak KK. Effect of Yoga-Based Intervention in Patients with Inflammatory Bowel Disease. Int J Yoga Ther. 2015 Jan 1;25(1):101–12.
2. Cramer H, Schäfer M, Schöls M, Köcke J, Elsenbruch S, Lauche R, et al. Randomised clinical trial: yoga vs written self-care advice for ulcerative colitis. Aliment Pharmacol Ther. 2017 Jun;45(11):1379–89.
P0904: Factors influencing postoperative bowel movement frequency following primary Ileo-Cecal resection in Crohn’s Disease patientsECCO'25Year: 2025
Authors: Naveh, H.(1)*;white, I.(2);wasserberg, N.(2);gurevich, N.(2);rozenstein, Y.(3);
(1)tel aviv university, medical school, ramat gan, Israel;(2)rabin medical center, general surgery, petah tikva, Israel;(3)tel aviv university, medical school, tel aviv, Israel;
P0905: Incidence, risk factors, and management of acne in IBD patients on JAK Inhibitors: A multicentre retrospective cohort study (The JAKNE Project)ECCO'25Year: 2025
Authors: Gonzalez LamaMD- PhD, Y.(1)*;Calvo, M.(2);Alfageme, F.(3);Guerrero, L.(1);Wang, S.(2);Ortiz, V.(3);Algara, M.(1);González-Partida, I.(2);Rafael de la Cruz, D.(1);Matallana, V.(2);Masedo, Á.(1);Botella, B.(2);Yela, C.(1);López, F.(1);Gutiérrez, P.(2);Olmedo, C.(1);Cudero, L.(1);Casis, B.(1);Vera, M.I.(2);
(1)Hospital Universitario 12 de Octubre, Digestive Medicine Department. Gastroenterology Section. IBD Unit., Madrid., Spain;(2)Hospital Universitario Puerta de Hierro., Gastroenterology Department. IBD Unit., Majadahonda. Madrid., Spain;(3)Hospital Universitario Puerta de Hierro, Dermatology Department., Majadahonda. Madrid., Spain;
P0906: A comparison of the transport-related carbon footprint of intravenous versus subcutaneous infliximabECCO'25Year: 2025
Authors: Cartledge, A.(1)*;Carbery, I.(1);Broglio, G.(2);Greer, D.(1);Selinger, C.(1);
(1)St James University Hospital, Department of Gastroenterology, Leeds, United Kingdom;(2)IRCCS Fondazione Policlinico San Matteo, Internal Medicine, Pavia, Italy;
1. NHS England. Delivering a 'Net Zero' National Health Service. 2020.
2. Pichler P-P, Jaccard IS, Weisz U, Weisz H. International comparison of health care carbon footprints. Environmental Research Letters. 2019. DOI 10.1088/1748-9326/ab19e1
3. Crohn’s and Colitis UK. Epidemiology Summary: Incidence and Prevalence of IBD in the United Kingdom. 2022. Accessed October 10, 2024. https://crohnsandcolitis.org.uk/media/4e5ccomz/epidemiology-summary-final.pdf
4. Rahmany S, Young D, Latter S, Cummings F. P96 Patient benefits of switching from intravenous to subcutaneous infliximab. Gut. 2023;72:A104
P0907: Health literacy and digital health literacy in Inflammatory Bowel Disease as conditions for individualized adapted digital health informationECCO'25Year: 2025
Authors: Maurud, S.(1)*;Lunde, L.(1);Moen, A.(1);Opheim, R.(2);
(1)Institute of Health and Society, Department of Public Health Science, Oslo, Norway;(2)Oslo University Hospital, Department of Gastroenterology, Oslo, Norway;
P0909: Efficacy of biologic therapy according to Crohn’s Disease location: a real-life observational studyECCO'25Year: 2025
Authors: Ferretti, F.(1)*;Cannatelli, R.(1);Molteni, C.B.(2);Carvalhas Gabrielli, A.M.(1);Carmagnola, S.(1);Maconi, G.(1,2);
(1)ASST Fatebenefratelli-Sacco, Gastroenterology Unit, Milan, Italy;(2)University of Milan, Department of Biomedical and Clinical Sciences, Milan, Italy;
1. Dulai PS, Singh S, Vande Casteele N, et al. Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases? Clin Gastroenterol Hepatol. 2019;17(13):2634-2643. doi: 10.1016/j.cgh.2019.04.0402.
2. Atreya R, Siegmund B. Location is important: differentiation between ileal and colonic Crohn's disease. Nat Rev Gastroenterol Hepatol. 2021;18(8):544-558. doi: 10.1038/s41575-021-00424-6.
3. Gordon H, Minozzi S, Kopylov U, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2024;18(10):1531-1555. doi: 10.1093/ecco-jcc/jjae091.
P0910: Evaluating Tryptophan as a Biomarker for Treatment Success in Ulcerative Colitis Patients Undergoing Mirikizumab TherapyECCO'25Year: 2025
Authors: Hatem, Y.(1)*;Maaß, C.(1);Marquardt , J.(1);Solbach, P.(1);
(1)University Medical Center Schleswig-Holstein- Campus Luebeck, Department of Medicine I, Luebeck, Germany;
Harris, D. M. M., Szymczak, S., Schuchardt, S., Labrenz, J., Tran, F., Welz, L., Graßhoff, H., Zirpel, H., Sümbül, M., Oumari, M., Engelbogen, N., Junker, R., Conrad, C., Thaçi, D., Frey, N., Franke, A., Weidinger, S., Hoyer, B., Rosenstiel, P., … Aden, K. (2024). Tryptophan degradation as a systems phenomenon in inflammation-an analysis across 13 chronic inflammatory diseases. www.thelancet.com
Nikolaus, S., Schulte, B., Al-Massad, N., Thieme, F., Schulte, D. M., Bethge, J., Rehman, A., Tran, F., Aden, K., Häsler, R., Moll, N., Schütze, G., Schwarz, M. J., Waetzig, G. H., Rosenstiel, P., Krawczak, M., Szymczak, S., & Schreiber, S. (2017). Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases. Gastroenterology, 153(6). https://doi.org/10.1053/j.gastro.2017.08.028
P0912: Factors associated with adherence to the Mediterranean diet in patients with Ulcerative Colitis after pouch surgeryECCO'25Year: 2025
Authors: Elial-Fatal, S.(1)*;Pfeffer-Gik, T.(1);Shelly, S.(1);H. Pauker, M.(1);Friedenberg, A.(1);Cohen, S.(1);Barkan, R.(1);Ollech, J.(1,2);Yanai, H.(1,2);Wasserberg, N.(2,3);White, I.(2,3);Dotan, I.(1,2);Godny, L.(1);
(1)Rabin Medical Center, Division of Gastroenterology, Petah-Tikva, Israel;(2)Tel Aviv University, Faculty of Medical and Health Sciences, Tel Aviv, Israel;(3)Rabin Medical Center, Colorectal Unit- Division of Surgery, Petah-Tikva, Israel;
P0913: Characteristics of patients with very late-onset ulcerative colitis: A single-center retrospective studyECCO'25Year: 2025
Authors: Ito, A.(1)*;kouroku, M.(2);Yonezawa, M.(2);Tani, K.(2);Futatsuki, R.(2);Ogawa, S.(2);Shigeki, Y.(2);Nakai, Y.(2);
(1)Tokyo Women's Medical University, Gastroentrology, Tokyo, Japan;(2)Tokyo Women's Medical University, Gastroenterology, Tokyo, Japan;
P0914: Clinical outcomes of dose-escalated adalimumab in Inflammatory Bowel Disease: A retrospective tertiary centre experienceECCO'25Year: 2025
Authors: Terlato, M.(1)*;Salehi , O.(1);Gondal, F.(1);Pillay, L.(1);Macrae, F.(1);Rentsch, C.(1);Dimovski, S.(1);Segal, J.P.(1);
(1)Royal Melbourne Hospital, Gastroenterology, Parkville, Australia;
1. JCrohn's Colitis. 2010 Oct 1;4(4):355-66. doi: 10.1016/j.crohns.2010.04.004
2. J Gastroenterol. 2017 May;52:535-54. doi: 10.1007/s00535-017-1324-3
3. Crohn's & Colitis 360. 2023 Oct 1;5(4):otad061. doi: 10.1093/crocol/otad061
P0915: Real-life experience with Upadacitinib in Crohn's disease (UPARECOL-CD Induction): A Colombian cohortECCO'25Year: 2025
Authors: Parra Izquierdo, L.V.(1,2)*;Frías-Ordoñez, J.(3);Barreto Perez, J.(4);Gil Parada, F.L.(5);Otero-Regino, W.(6,7);Tovar Fierro, G.M.(8);Florez-Sarmiento, C.(1,9);
(1)Hospital Internacional de Colombia, Gastroenterology, Bucaramanga, Colombia;(2)INMUBO Grupo de Inmunología celular y molecular - Universidad El Bosque., Immunology, Bogota, Colombia;(3)National University of Colombia, Gastroenterology, Bogotá, Colombia;(4)Medicarte, Gastroenterology, Bogota, Colombia;(5)Clinica Universitaria Colombia, Gastroenterology, Bogota, Colombia;(6)National University of Colombia, Gastroenterology, Bogota, Colombia;(7)Centro de Gastroenterologia, Gastroenterology, Bogota, Colombia;(8)Gastrocal, Gastroenterology, Bucaramanga, Colombia;(9)INMUBO Grupo de Inmunología celular y molecular - Universidad El Bosque., Inmunology, Bogota, Colombia;
P0916: Lusvertikimab is efficacious in severe ulcerative colitis (UC) patients with high fecal calprotectin (FCP): results from the CoTikiS studyECCO'25Year: 2025
Authors: Reinisch, W.(1)*;Kierkus, J.(2);Corallo, F.(3);Bourreille, A.(4);
(1)Medical University of Vienna, Department of Internal Medicine, Vienna, Austria;(2)The Children's Memorial Health Institute, Department of Gastroenterology- Hepatology- Feeding Disorders and Pediatrics, Warsaw, Poland;(3)Ose-Immunotherapeutics, Clinical Development, Paris, France;(4)Nantes University- Institut des Maladies de l’Appareil Digestif- CHU Nantes, Department of Gastroenterology, Nantes, France; CoTikiS
P0917: Corticosteroid sparing effects of treatment with guselkumab in patients with moderate to severely active Crohn’s disease: Phase 3 GALAXI 2/3 results through week 48ECCO'25Year: 2025
Authors: Panés, J.(1)*;Hisamatsu, T.(2);Armuzzi, A.(3);Terry, N.A.(4);Salese, L.(4);Van Rampelbergh, R.(5);Yee, J.(4);Wan, K.Y.(6);Yang, Z.(7);Pin, S.(4);Sands, B.E.(8);Rubin, D.T.(9);
(1)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Medicine, Barcelona, Spain;(2)Kyorin University, Gastroenterology and Hepatology, Tokyo, Japan;(3)IBD Center- IRCCS Humanitas Research Hospital- Rozzano, Medicine, Milan, Italy;(4)Janssen Research & Development- LLC, Immunology, Spring House, United States;(5)Janssen Research & Development- LLC, Immunology, Antwerp, Belgium;(6)Janssen Research & Development- LLC, Biostatistics, Basel, Switzerland;(7)Janssen Research & Development- LLC, Biostatistics, Spring House, United States;(8)Dr. Henry D Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, Medicine, New York, United States;(9)University of Chicago School of Medicine Inflammatory Bowel Disease Center, Medicine, Chicago, United States;
P0918: Identification of a serum proteomics signature linked with anti-TNF therapy response outcomes in Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Bourgery, M.(1,2)*;Bernardes, J.P.(2);Wittig, M.(2);Kimmig, F.(2);Mishra, N.(2);Franke, A.(2);Aden, K.(1,2);Schreiber, S.(1);Rosenstiel, P.(2);Tran, F.(1,2);
(1)University Hospital Schleswig-Holstein- Campus Kiel, Department of Internal Medicine I/Gastroenterology, Kiel, Germany;(2)University Hospital Schleswig-Holstein- Campus Kiel, Insitute of Clinical Molecular Biology, Kiel, Germany;
(1) Mishra N, et al. Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease. Genome Med. 2022 Sep 24;14(1):110. doi: 10.1186/s13073-022-01112-z. PMID: 36153599; PMCID: PMC9509553.
This project has received funding from the DFG Cluster of Excellence 2167 "Precision medicine in chronic inflammation", the BMBF (e:Med Network iTREAT 01ZX2202A, and GUIDE-IBD 031L0188A), and the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 831434 (3TR) and No 853995 (ImmUniverse).The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. The content provided in this publication reflects the author's views only. Neither the Innovative Medicines Initiative (IMI JU) nor the European Commission are responsible for any use that may be made of the information it contains.
P0919: Correlation between trough levels of risankizumab and clinical and biological remission in patients with moderate to severe Crohn's disease: a retrospective multicenter study (RISE-CD)ECCO'25Year: 2025
Authors: Sequier, L.(1)*;Altwegg, R.(2);Barrau, M.(3);Bozon, A.(2);Nancey, S.(4);Boschetti, G.(5);Roblin, X.(6);Caillo, L.(1);
(1)CHU Caremeau- Nîmes, Hepato-gastro-enterology, Nîmes, France;(2)CHU Montpellier, Hepato-gastro-enterology, Montpellier, France;(3)University Hospital of Saint-Etienne, Department of Gastroenterology, Saint-Etienne, France;(4)Lyon-Sud Hospital- CHU de Lyon- University Claude Bernard Lyon 1 and CIRI-INSERM U1111, Department of Gastroenterology-, Lyon, France;(5)Lyon Sud Hospital- Hospices Civils de Lyon- University Claude Bernard Lyon 1- France- INSERM U1111, Departement of Gastroenterology, Lyon, France;(6)University Hospital of Saint-Etienne, Departement of Gastroenterology, Saint-Etienne, France;
P0920: Long term follow-up of patients with ulcerative colitis after suspension of infliximab for stable deep remissionECCO'25Year: 2025
Authors: Dussias, N.(1)*;Melotti, L.(1);Vanigli, N.(2);Calabrese, C.(2);Gionchetti, P.(2);Rizzello, F.(2);
(1)IBD Unit- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Medical and Surgical and Sciences, Bologna, Italy;(2)IBD Unit- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Medical and Surgical and Sciences- University of Bologna, Bologna, Italy;
P0921: Management of anti-TNF inmunogenicity in inflamatory bowel disease: data from a tertiary care hospitalECCO'25Year: 2025
Authors: López Cardona, J.(1)*;Mesonero Gismero , F.(1);García de la Filia Molina , I.(1);Fernández Fernández , C.(1);Roy Ariño, G.(2);Gramage Caro , T.(3);Albillos Martínez, A.(1);
(1)Hospital Universitario Ramón y Cajal, Gastroenterology and Hepatology Department, Madrid, Spain;(2)Hospital Universitario Ramón y Cajal, Inmunology department, Madrid, Spain;(3)Hospital Universitario Ramón y Cajal, Pharmacy Department, Madrid, Spain;
P0922: Usefulness of Ustekinumab levels in clinical practice: a single center experienceECCO'25Year: 2025
Authors: Garcia De La Filia Molina, I.(1)*;Mesonero Gismero , F.(1);López Cardona, J.(1);Fernández Fernández, C.(1);Roy Ariño, G.(2);Gramage Caro , T.(3);Albillos Martínez, A.(1);López San Román, A.(1);
(1)Ramon y Cajal Hospital, Gastroenterology, Madrid, Spain;(2)Ramon y Cajal Hospital, Immunology, Madrid, Spain;(3)Ramon y Cajal Hospital, Pharmacy, Madrid, Spain;
Rodríguez-Moranta F et al. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis. Gastroenterología y Hepatología 2024.
P0923: Impact of Inflammatory Bowel Disease on Women’s HealthECCO'25Year: 2025
Authors: Bhardwaj, A.(1)*;SinghD.M., A.(1);Sharma, R.(1);Bansal, N.(2);Singh, D.(2);Midha, V.(3);Sood, A.(1);
(1)Dayanand Medical College and Hospital, Gastroenterology, Ludhiana, India;(2)Dayanand Medical College and Hospital, Research and Development, Ludhiana, India;(3)Dayanand Medical College and Hospital, Medicine, Ludhiana, India;
